Comparison between physiologically based pharmacokinetic and population pharmacokinetic modelling to select paediatric doses of gepotidacin in plague. Issue 2 (2nd September 2021)

• Record Type: Journal Article
• Authors: Nguyen, Dung; Shaik, Jafar Sadik; Tai, Guoying; Tiffany, Courtney; Perry, Caroline; Dumont, Etienne; Gardiner, David; Barth, Aline; Singh, Rajendra; Hossain, Mohammad
• Is Part Of: British journal of clinical pharmacology. Volume 88:Issue 2(2022)
• Page Start: 416
• Page End: 428
• Publication Date: 2021-09-02
• Subjects: simulation -- modelling -- PBPK -- pharmacodynamics -- population analysis; Pharmacology -- Periodicals; Drugs -- Periodicals; 615.1
• DOI: 10.1111/bcp.14996
• Languages: English
• ISSNs: 0306-5251

Abstract

Abstract : Aims: To develop physiologically based pharmacokinetic (PBPK) and population pharmacokinetic (PopPK) models to predict effective doses of gepotidacin in paediatrics for the treatment of pneumonic plague ( Yersinia pestis ). Methods: A gepotidacin PBPK model was constructed using a population‐based absorption, distribution, metabolism and excretion simulator, Simcyp®, with physicochemical and in vitro data, optimized with clinical data from a dose‐escalation intravenous (IV) study and a human mass balance study. A PopPK model was developed with pooled PK data from phase 1 studies with IV gepotidacin in healthy adults. Results: For both the PopPK and PBPK models, body weight was found to be a key covariate affecting gepotidacin clearance. With PBPK, ~90% of the predicted PK for paediatrics fell between the 5th and 95th percentiles of adult values except for subjects weighing ≤5 kg. PopPK‐simulated paediatric means for C max and AUC(0‐τ) were similar to adult exposures across various weight brackets. The proposed dosing regimens were weight‐based for subjects ≤40 kg and fixed‐dose for subjects >40 kg. Comparison of observed and predicted exposures in adults indicated that both PBPK and PopPK models achieved similar AUC and C max for a given dose, but the C max predictions with PopPK were slightly higher than with PBPK. The two models differed on dose predictions in children <3 months old. The PopPK model may be suboptimal for low age groups due to the absence of maturation characterization of drug‐metabolizing enzymes involved with clearance in adults. Conclusions: Both PBPK and PopPK approaches can reasonably predict gepotidacin exposures in children.